Background: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid study found no evidence of a beneficial effect of statin-fibrate combined treatment, compared to statins alone, on cardiovascular outcomes and mortality in type 2 diabetes mellitus after 5 years of active treatment. However, a beneficial reduction in major CVD events was shown in a pre-specified sub-group of participants with dyslipidemia. The extended follow-up of this trial provides the opportunity to further investigate possible beneficial effects of fibrates in this group of patients. We aimed to evaluate possible "legacy effects" of fibrate add-on therapy on mortality and major cardiovascular outcomes in patients with dyslipidemia.
Methods: The ACCORD-lipid study was a randomized controlled trial of 5518 participants assigned to receive simvastatin plus fenofibrate vs simvastatin plus placebo. After randomized treatment allocation had finished at the end of the trial, all surviving participants were invited to attend an extended follow-up study (ACCORDION) to continue prospective collection of clinical outcomes. We undertook a secondary analysis of trial and post-trial data in patients who had dyslipidemia. The primary outcome was all-cause and cardiovascular mortality, and secondary outcomes were nonfatal myocardial infarction, stroke, congestive heart failure and major coronary heart disease. We used an intention-to-treat approach to analysis to make comparisons between the original randomized treatment groups.
Results: 853 participants with dyslipidemia had survived at the end of the trial. Most participants continued to use statins, but few used fibrates in either group during the post-trial period. The incidence rates in the fenofibrate group were lower with respect to all-cause mortality, CVD mortality, nonfatal myocardial infarction, congestive heart failure and major coronary heart disease than those in the placebo group over a post-trial follow-up. Allocation to the combined fibrate-statin treatment arm during the trial period had a beneficial legacy effect on all-cause mortality (adjusted HR = 0.65, 95% CI 0.45-0.94; P = 0.02).
Conclusions: Fibrate treatment during the initial trial period was associated with a legacy benefit of improved survival over a post-trial follow-up. These findings support re-evaluation of fibrates as an add-on strategy to statins in order to reduce cardiovascular risk in diabetic patients with dyslipidemia. Trial registration clinicaltrials.gov, Identifier: NCT00000620.
Keywords: Cardiovascular diseases; Dyslipidemia; Fibrate; Legacy effect; Type 2 diabetes.
Conflict of interest statement
The authors declare that they have no competing interests.
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24. Cardiovasc Diabetol. 2010. PMID: 20550659 Free PMC article.
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.JAMA Cardiol. 2017 Apr 1;2(4):370-380. doi: 10.1001/jamacardio.2016.4828. JAMA Cardiol. 2017. PMID: 28030716 Free PMC article. Clinical Trial.
Hyperlipidaemia and cardiovascular disease: do fibrates have a role?Curr Opin Lipidol. 2011 Aug;22(4):270-6. doi: 10.1097/MOL.0b013e32834701c3. Curr Opin Lipidol. 2011. PMID: 21519250 Review.
The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus.Clin Lipidol. 2011;6(1):9-20. doi: 10.2217/clp.10.84. Clin Lipidol. 2011. PMID: 26207146 Free PMC article.
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Cardiovasc Diabetol. 2012. PMID: 23057687 Free PMC article. Review.